Doctor Håkan Mellstedt was born in Lund, Sweden, October 23, 1942. He received his M.D. in 1969 and Ph.D. in 1974, both at the Karolinska Institutet, Stockholm, Sweden. The title of his academic thesis was "Human plasma cell myeloma a B-lymphocyte malignancy. An in vitro immunological study". He was Assistant Professor at the Karolinska Institutet 1975-1978, Associate Professor of Internal Medicine 1978-1987 and 1987-1996 Associate Professor of Oncology. In 1996 he was appointed Professor of Experimental Oncology and Head of the Division of Experimental Oncology, Uppsala University, Uppsala, Sweden. In 1999 he was appointed Professor of Medical Oncology/Oncologic Biotherapy at the Karolinska Institutet and Chief Physician at the Department of Oncology. He has specialist certificates in Hematology, Oncology and Internal Medicine.
Doctor Mellstedt is a member of the Scientific Committee of the Swedish Cancer Society, the Scientific Committee of the Swedish Childhood Cancer Society. Scientific Secretary of the Cancer Society in Stockholm and the King Gustaf V Jubilee Fund and a member of the Board of Directors of these two foundations. He is a member of the National Representatives of ESMO (European Society of Medical Oncology) and has acted in the Steering Committee of ESMO. He was the Chairman of the Swedish Society of Oncology between 1993-2000. He is a member of the Scientific Advisory Board or several international pharmaceutical/biotechnological companies developing biotherapeutic strategies in malignant diseases.
In 1989 Doctor Mellstedt received the Alfaferone Prize awarded by the Italian Institute of Immunology for his achievements on interferon therapy in multiple myeloma, especially the combination of interferon and chemotherapeutics. In 2001 he received the J. Waldenstrom Award for exceptional contributions to the treatment and biology of multiple myeloma.
Doctor Mellstedt has published over 375 articles in scientific journals and a lot of chapters in textbooks. He is currently on the Editorial Board of several international scientific journals. His research fields are multiple myeloma, chronic lymphocytic leukemia and the development of immunotherapy (monoclonal antibodies, tumor vaccines) in malignant diseases. In multiple myeloma Doctor MellstedtÕs major achievements are: the first to describe the existence of idiotype expressing pre-plasma cells belonging to the myeloma tumor clone (1974); the first introduced interferon treatment in multiple myeloma (1979); he originally described idiotype reactive T-cells in myeloma in man (1991) and was the first to perform idiotype vaccination in myeloma patients (1994).